BECTON, DICKINSON AND COMPANY (NYSE:BDX) Files An 8-K Other EventsItem 8.01. Other Events.
Becton, Dickinson and Company (“BD”) is registering 487,989 shares (the “Shares”) of its common stock, par value $1.00 per share, under BD’s registration statement on Form S-3 (File No.333-206020) (the “Registration Statement”), as supplemented by a prospectus supplement, dated as of December29, 2017, filed with the Securities and Exchange Commission on December29, 2017. The Shares are issuable to certain former employees of C. R. Bard, Inc. and employees of certain former affiliates of C. R. Bard, Inc. upon the exercise of certain stock-settled stock appreciation rights issued under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan, as amended and restated, that we have agreed to substitute for outstanding equity awards previously granted by C. R. Bard, Inc. in connection with our acquisition of C. R. Bard, Inc.
Attached hereto and incorporated by reference to the Registration Statement as Exhibit 5.1 is a copy the opinion of Gary DeFazio, as Senior Vice President, Corporate Secretary and Associate General Counsel for BD.
Item 8.01. Financial Statements and Exhibits.
(d) Exhibits
BECTON DICKINSON & CO ExhibitEX-5.1 2 d489043dex51.htm EX-5.1 EX-5.1 Exhibit 5.1 December 29,…To view the full exhibit click here
About BECTON, DICKINSON AND COMPANY (NYSE:BDX)
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.
